The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acquired Orphan Blood Diseases Therapeutics Market Research Report 2024
Synopsis
Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack of red blood cells in blood, which in turn results in a decrease in platelet numbers. This decrease in platelet number causes anemia and thrombosis.
The global Acquired Orphan Blood Diseases Therapeutics market was valued at US$ 928.2 million in 2023 and is anticipated to reach US$ 1229.3 million by 2030, witnessing a CAGR of 4.1% during the forecast period 2024-2030.
Soliris (eculizumab) is a perfect example of a successful orphan blood disease drug. PNH is a potentially life-threatening blood disease, characterised by severe anemia caused by the destruction of red blood cells in the bloodstream. Bone marrow transplants can provide a cure, but the high risk procedure is suitable for only a few patients. Treatment methods include blood transfusions, iron therapy, and growth factors, but monoclonal antibody
This report aims to provide a comprehensive presentation of the global market for Acquired Orphan Blood Diseases Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acquired Orphan Blood Diseases Therapeutics.
Report Scope
The Acquired Orphan Blood Diseases Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acquired Orphan Blood Diseases Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acquired Orphan Blood Diseases Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alexion Pharmaceuticals
Amgen
Celgene
Eli Lilly
Sanofi
GlaxoSmithKline
Cyclacel Pharmaceuticals
Onconova Therapeutics
Incyte
CTI BioPharma
Segment by Type
Medication
Bone Marrow Transplant
Blood Transfusion
Immunotherapy
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acquired Orphan Blood Diseases Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack of red blood cells in blood, which in turn results in a decrease in platelet numbers. This decrease in platelet number causes anemia and thrombosis.
The global Acquired Orphan Blood Diseases Therapeutics market was valued at US$ 928.2 million in 2023 and is anticipated to reach US$ 1229.3 million by 2030, witnessing a CAGR of 4.1% during the forecast period 2024-2030.
Soliris (eculizumab) is a perfect example of a successful orphan blood disease drug. PNH is a potentially life-threatening blood disease, characterised by severe anemia caused by the destruction of red blood cells in the bloodstream. Bone marrow transplants can provide a cure, but the high risk procedure is suitable for only a few patients. Treatment methods include blood transfusions, iron therapy, and growth factors, but monoclonal antibody
This report aims to provide a comprehensive presentation of the global market for Acquired Orphan Blood Diseases Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acquired Orphan Blood Diseases Therapeutics.
Report Scope
The Acquired Orphan Blood Diseases Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acquired Orphan Blood Diseases Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acquired Orphan Blood Diseases Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alexion Pharmaceuticals
Amgen
Celgene
Eli Lilly
Sanofi
GlaxoSmithKline
Cyclacel Pharmaceuticals
Onconova Therapeutics
Incyte
CTI BioPharma
Segment by Type
Medication
Bone Marrow Transplant
Blood Transfusion
Immunotherapy
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acquired Orphan Blood Diseases Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Medication
1.2.3 Bone Marrow Transplant
1.2.4 Blood Transfusion
1.2.5 Immunotherapy
1.3 Market by Application
1.3.1 Global Acquired Orphan Blood Diseases Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acquired Orphan Blood Diseases Therapeutics Market Perspective (2019-2030)
2.2 Acquired Orphan Blood Diseases Therapeutics Growth Trends by Region
2.2.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Acquired Orphan Blood Diseases Therapeutics Market Dynamics
2.3.1 Acquired Orphan Blood Diseases Therapeutics Industry Trends
2.3.2 Acquired Orphan Blood Diseases Therapeutics Market Drivers
2.3.3 Acquired Orphan Blood Diseases Therapeutics Market Challenges
2.3.4 Acquired Orphan Blood Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acquired Orphan Blood Diseases Therapeutics Players by Revenue
3.1.1 Global Top Acquired Orphan Blood Diseases Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Acquired Orphan Blood Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acquired Orphan Blood Diseases Therapeutics Revenue
3.4 Global Acquired Orphan Blood Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Acquired Orphan Blood Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acquired Orphan Blood Diseases Therapeutics Revenue in 2023
3.5 Acquired Orphan Blood Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Acquired Orphan Blood Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Acquired Orphan Blood Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acquired Orphan Blood Diseases Therapeutics Breakdown Data by Type
4.1 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Type (2025-2030)
5 Acquired Orphan Blood Diseases Therapeutics Breakdown Data by Application
5.1 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Acquired Orphan Blood Diseases Therapeutics Market Size (2019-2030)
6.2 North America Acquired Orphan Blood Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2019-2024)
6.4 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acquired Orphan Blood Diseases Therapeutics Market Size (2019-2030)
7.2 Europe Acquired Orphan Blood Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2019-2024)
7.4 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size (2019-2030)
9.2 Latin America Acquired Orphan Blood Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alexion Pharmaceuticals
11.1.1 Alexion Pharmaceuticals Company Detail
11.1.2 Alexion Pharmaceuticals Business Overview
11.1.3 Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Introduction
11.1.4 Alexion Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.1.5 Alexion Pharmaceuticals Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Acquired Orphan Blood Diseases Therapeutics Introduction
11.2.4 Amgen Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Celgene
11.3.1 Celgene Company Detail
11.3.2 Celgene Business Overview
11.3.3 Celgene Acquired Orphan Blood Diseases Therapeutics Introduction
11.3.4 Celgene Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.3.5 Celgene Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Acquired Orphan Blood Diseases Therapeutics Introduction
11.4.4 Eli Lilly Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.4.5 Eli Lilly Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Acquired Orphan Blood Diseases Therapeutics Introduction
11.5.4 Sanofi Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.5.5 Sanofi Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Introduction
11.6.4 GlaxoSmithKline Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.6.5 GlaxoSmithKline Recent Development
11.7 Cyclacel Pharmaceuticals
11.7.1 Cyclacel Pharmaceuticals Company Detail
11.7.2 Cyclacel Pharmaceuticals Business Overview
11.7.3 Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Introduction
11.7.4 Cyclacel Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.7.5 Cyclacel Pharmaceuticals Recent Development
11.8 Onconova Therapeutics
11.8.1 Onconova Therapeutics Company Detail
11.8.2 Onconova Therapeutics Business Overview
11.8.3 Onconova Therapeutics Acquired Orphan Blood Diseases Therapeutics Introduction
11.8.4 Onconova Therapeutics Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.8.5 Onconova Therapeutics Recent Development
11.9 Incyte
11.9.1 Incyte Company Detail
11.9.2 Incyte Business Overview
11.9.3 Incyte Acquired Orphan Blood Diseases Therapeutics Introduction
11.9.4 Incyte Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.9.5 Incyte Recent Development
11.10 CTI BioPharma
11.10.1 CTI BioPharma Company Detail
11.10.2 CTI BioPharma Business Overview
11.10.3 CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Introduction
11.10.4 CTI BioPharma Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2019-2024)
11.10.5 CTI BioPharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
